Abstract
Cholesterol-lowering statin medications are a safe and effective therapy to lower cholesterol and reduce the risk of cardiovascular events. Yet physician prescribing patterns and patient adherence remain suboptimal in Canada and the United States, often due to pervasive misconceptions. The Community Heart Outcomes Improvement and Cholesterol Education Study (CHOICES) is a pragmatic, registry-based, cluster randomized controlled trial that aims to improve cholesterol management through appropriate statin use in adults and to ultimately reduce cardiovascular events in high-risk communities across Ontario. The trial uses an innovative, multicomponent intervention and implementation approach that includes audit and feedback reports for family physicians and educational materials and tools for patients.

The Issue
Cardiovascular disease (CVD) remains a highly prevalent chronic disease in Canada and costs the province of Ontario alone approximately $10.5 billion in direct healthcare spending annually (Chu et al. 2019). Statins are a class of medications commonly used to reduce the level of low-density lipoprotein, sometimes referred to as “bad” cholesterol, and have been shown to reduce the risk of first (i.e., primary prevention) and recurrent (i.e., secondary prevention) cardiac events in high-risk middle-aged adults by about 25% (Cholesterol Treatment Trialists’ Collaborators 2005 2010). Despite the well-established benefit of cholesterol-lowering statin therapy and frequently touted reputation as the “wonder drug” for CVD prevention, therapeutic cholesterol management by means of statin prescribing and adherence remains suboptimal in both Canada and the United States (Hennessy et al. 2016; Sparrow et al. 2019a, 2019b). For instance, patients who are eligible for statin therapy often report never being offered statins by their physician or report discontinuing their therapy due to perceptions and fear of side effects (Bradley et al. 2019). For patients on statins, many are often not on the guideline-recommended dosage that achieves the greatest preventive impact (Navar et al. 2017).

The Approach
Barriers and facilitators
Although barriers to optimal cholesterol management have been identified in other jurisdictions, an Ontario-based study of community-specific factors was warranted to help optimize our intervention. During the study’s first six months, the Team for Implementation, Evaluation and Sustainability with the Knowledge Translation Program at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital conducted a formative...
assessment of barriers and facilitators to optimal cholesterol management in high-cardiovascular-risk communities. The assessment consisted of telephone interviews with a purposive sample of patients and family physicians. Findings from these interviews helped identify implementation strategies that may be considered for improving uptake of cholesterol management activities. These included but were not limited to the following:

- use of mass media campaigns to encourage cardiovascular risk assessment and adherence to cholesterol medications;
- distribution of educational materials to empower patients to be active participants in their cholesterol management activities, including in clinic waiting rooms as a patient-mediated strategy also targeting physicians; and
- use of audit and feedback tools that are prepared at a community level for primary care.

The recommendations yielded from the assessment of barriers and facilitators helped inform the intervention strategies used for the CHOICES trial.

Patient engagement
Because patient engagement is key to all facets of the trial work, we established a CHOICES patient partner panel of eight individuals from across Ontario who will be involved in the project over its life cycle. The panel’s role is to offer insight on various aspects of the project, including intervention materials and implementation strategies, and provide a public lens on the real-world implications of cholesterol management in different parts of the province.

Outcome measurement
The CHOICES trial interventions target adults without a history of CVD who are living in Ontario communities that have higher than average rates of cardiovascular events. A group of control communities will not receive the intervention tools to rigorously assess the impact of care patterns and outcomes. Our Cardiovascular Health in Ambulatory Care Research Team (CANHEART) “big data” registry, created through linkage of more than 19 population databases housed at ICES, has attracted increasing attention as a novel, less costly and more efficient method for conducting clinical trials in health research (Tu et al. 2015). The registry will be used in place of primary data collection to measure outcomes in the intervention and control communities.

The primary trial outcome will be the proportion of residents (aged 66 to 75) in each community at intermediate and high risk of CVD taking statins, as measured using the CANHEART registry at the beginning and completion of the three-year intervention period. Secondary process of care outcomes will also be measured at baseline and study completion, including clinical events and ongoing process measures that will track the number of downloads of our cholesterol management resources, the number of visits to the study website and other measures of knowledge translation available through online analytics.

Process evaluations will be conducted by the Team for Implementation, Evaluation and Sustainability to aid in evaluating the implementation strategies throughout the course of the study and to better understand implementation quality at each site from the perspectives of those who are directly and indirectly involved with implementation. A pre- and post-implementation survey will also be conducted to measure knowledge, attitudes, confidence and intentions related to cholesterol management and cardiovascular health.

The Intervention
In the fall of 2019, we launched the first phase of our multicomponent intervention strategy, which was aimed at both patients and family physicians. The launch consisted of a targeted implementation of a cardiovascular risk management physician report card on the status of cardiovascular preventive care in each community and tailored patient education materials on cholesterol management and cardiovascular health. The cardiovascular risk management report cards will be issued annually to family physicians in the intervention communities for the next three years and will provide community-level data on nine main indicators of cardiovascular risk management. Each community is provided with its overall ranking compared to all 76 health regions in Ontario (except two with inadequate amounts of data), as well as indicators on risk factor screening. The report cards also provide rates of statin use among 66- to 75-year-olds in various subgroups at high risk for CVD and an indicator on statin adherence and cholesterol treatment target achievement.

Benchmarks are an important part of the report cards as these provide family physicians with high but achievable goals in their own practice for the included indicators. In addition to providing the community with their own data, each indicator also reports:

1. the Achievable Benchmark of Care (ABC) representing the value for the top 10% of performers (Weissman et al. 1999),
2. the value for the top performer in each indicator and
3. the highest reported values in a comparable health system from existing literature.

In addition to providing community-level data and benchmarking, two pages of the report are devoted to providing tips on improving cholesterol screening and statin prescribing and adherence. Information included in this section is based on the Canadian Cardiovascular Society’s 2016 guidelines for dyslipidemia (Anderson et al. 2016), which are evidence based and the
current Canadian standard of practice. Preliminary results of the primary and secondary outcomes will become available as data linkage is updated across the CANHEART databases and as respondents complete process evaluation surveys.

Our team has also developed patient-centred print materials (e.g., waiting room posters, one-page flyers and 12-page booklets) that can educate the public about the indications for cholesterol screening, heart disease risk and benefits and risks of cholesterol-lowering therapy. Materials specifically address the barriers and facilitators of optimal cholesterol management identified from our qualitative patient interviews and are meant to empower patients with actionable resources and encourage informed discussions with their physicians. Our materials also include general advice about CVD risk reduction (e.g., smoking cessation, diet and physical activity), although the primary focus is on cholesterol and statins.

As part of our dissemination of the patient and physician “toolbox” of cholesterol management resources, we chose a two-pronged approach of both digital and print distribution to allow for maximum reach. Our CANHEART website serves as the hub for accessing study materials, whereas print copies of patient materials and report cards were mailed, respectively, to various community organizations and family physician practices. On our website, a designated URL (www.canheart.ca/choices) will provide general study information, link to the patient materials and physician reports accessible to those with a postal code in the intervention regions and highlight the work of our patient partner panel and investigator team. In addition, we have created a three-and-a-half-minute promotional video that explains the purpose of the project and is available on YouTube (https://youtu.be/QF285N3ytO8). We also have a Twitter feed (@CANHEART_News) for sharing promotional materials, information on the study and general research and new data on cholesterol and cardiovascular health by our co-investigators and partners.

Moving Forward
We hope that this work can ultimately serve as a flagship project for prompt feedback of care across communities in Ontario, across Canada and beyond. Our interventions are pragmatic and interactive, with the ability to serve as a learning health system to inform evidence-based practice and policy changes. By improving the implementation of guideline-recommended preventive therapy among those at risk of experiencing a cardiovascular event, we hope to inevitably save direct costs associated with in-patient care, cardiac rehabilitation and ambulatory services and indirect costs attributed to loss of work and premature death. Our study may also improve patient experience and quality of care by empowering patients with access to real-time, evidence-based information on the benefits and risks of statins in cardiovascular health. We will launch our next phase of study interventions in 2020 and 2021, and all study interventions will be made publicly available at the conclusion of the study in late 2022. For more information, visit www.canheart.ca/choices.

Funding and Disclosures
The CHOICES study is supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care. This study was also supported by a Chronic Diseases Team operating grant from the Institute of Circulatory and Respiratory Health-Canadian Institutes of Health Research (CIHR) (grant ICA 118349), a CIHR Strategy for Patient-Oriented Research Innovative Clinical Trial Multi-Year Grant (grant MYG 151211), a CIHR foundation grant (grant FDN-143313) and an operating grant from the Heart and Stroke Foundation of Canada (grant G-15-0009034). The analyses, conclusions, opinions and statements expressed herein are solely those of the authors and do not reflect those of the funding or data sources; no endorsement is intended or should be inferred.

Parts of the cardiovascular risk management report cards are based on data and information compiled and provided by the Ontario Ministry of Health and Long-Term Care, the Canadian Institute for Health Information and IMS Brogan. Data sets were linked using unique encoded identifiers and analyzed at ICES. We also thank Alia Januwalla, former research coordinator at the Knowledge Translation Program of the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, for her contributions to the planning and coordination of the implementation process evaluation. Dr. Udell is supported by a Heart and Stroke Foundation National New Investigator-Ontario Clinician Scientist Award and an Ontario Ministry of Research Innovation and Science Early Researcher Award. Dr. Udell reports receiving personal fees for consulting for or honoraria from Amgen, AstraZeneca, Boehringer-Ingelheim, Janssen, Merck, Novartis and Sanofi and receiving grant support from AstraZeneca, Novartis and Sanofi.

Note
1. In memory of Dr. Jack Tu (1965–2018), former principal investigator of the CANHEART CHOICES initiative.

References


About the Authors

Laura E. Ferreira-Legere, RN, MScN, is a research project manager with the CHOICES trial and the Cardiovascular Research Program at ICES in Toronto.

Anna Chu, MHSc, is a senior epidemiologist with the Cardiovascular Research Program at ICES.

Mohammed Rashid, MSc, is an analyst with the Cardiovascular Research Program at ICES.

Atul Sivaswamy, MSc, is an analyst with the Cardiovascular Research Program at ICES.

Tara O’Neill, BES, is a research assistant with the Cardiovascular Research Program at ICES.

Christine Marquez, BSc, is a research coordinator with the Knowledge Translation Program at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto.

Richelle Baddeliyanage, BSc, is a research assistant with the Knowledge Translation Program at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital.

Sharon Straus, MD, MSc, FRCPC, PhD, is director of the Knowledge Translation Program at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, where she is physician-in-chief, and a professor of medicine at the University of Toronto.

Jacob A. Udell, MD, MPH, FRCPC, is a cardiologist and clinician-scientist at Women’s College Hospital and the Peter Munk Cardiac Centre of the University Health Network and an associate professor of medicine at the University of Toronto. He is an adjunct scientist at ICES and co-principal investigator for the CHOICES trial. Dr. Udell can be contacted by e-mail at jay.udell@utoronto.ca.